Biontech SE

BNTX

96.740USD

-7.570-7.26%

Close 09/12, 16:00（ET）Quotes delayed by 15 min

Score

Industry at a Glance

Industry Ranking

38 / 507

Overall Ranking

167 / 4724

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 23 analysts

Buy

Current Rating

136.529

Target Price

+41.13%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.

Turnaround to Loss

The company's performance has turned to a loss, with the latest annual loss of USD 642.62M.%!(EXTRA int=2)

Undervalued

The company’s latest PE is -67.77, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 205.26M shares, decreasing 2.06% quarter-over-quarter.

Held by Baillie Gifford

Star Investor Baillie Gifford holds 8.04M shares of this stock.

The company's current financial score is 8.16, which is higher than the Biotechnology & Medical Research industry's average of 6.80. Its financial status is robust, and its operating efficiency is average. Its latest quarterly revenue reached 182.80M, representing a year-over-year decrease of 2.56%, while its net profit experienced a year-over-year decrease of 31.96%.

Score

Industry at a Glance

Previous score

8.16

Change

0



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

8.04

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

6.80

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

8.67

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.31

Key Metrics

Free cash flow

No Data

The company’s current valuation score is 1.20, which is lower than the Biotechnology & Medical Research industry's average of 1.64. Its current P/E ratio is -72.16, which is -108.30% below the recent high of 5.99 and 49.72% above the recent low of -36.28.

Score

Industry at a Glance

Previous score

1.20

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 38/507

No Data

The company’s current earnings forecast score is 7.90, which is lower than the Biotechnology & Medical Research industry's average of 7.96. The average price target for Biontech SE is 136.50, with a high of 171.00 and a low of 82.11.

Score

Industry at a Glance

Previous score

7.91

Change

0

Support & Resistance

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The company’s current price momentum score is 6.33, which is lower than the Biotechnology & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 111.84 and the support level at 97.85, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.44

Change

0.42

Support & Resistance

No Data

Institutional Confidence

Currency: USD Updated：2025-09-12

The company’s current institutional recognition score is 7.00, which is higher than the Biotechnology & Medical Research industry's average of 6.02. The latest institutional shareholding proportion is 85.38%, representing a quarter-over-quarter decrease of 0.22%. The largest institutional shareholder is Baillie Gifford, holding a total of 8.04M shares, representing 3.34% of shares outstanding, with 2.38% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

0

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

AT Impf GmbH

101.85M

-0.62%

Medine GmbH

40.13M

-0.75%

Baillie Gifford & Co.

Star Investors

8.16M

-0.74%

Fidelity Management & Research Company LLC

5.95M

-7.69%

Flossbach von Storch AG

4.26M

-3.34%

PRIMECAP Management Company

Star Investors

4.05M

-5.81%

Pfizer Inc

3.66M

--

Sahin (Ugur MD)

2.05M

-26.11%

Temasek Holdings Pte. Ltd.

1.81M

--



1

2



The U.S. Dollar Index is currently in a neutral state, which has a minor effect on the Biotechnology & Medical Research mixed industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The company’s current risk assessment score is 5.11, which is higher than the Biotechnology & Medical Research industry's average of 3.51. The company's beta value is 1.40. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.

Biontech SE

BNTX

6.39 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Insmed Inc

INSM

7.28 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Stoke Therapeutics Inc

STOK

7.13 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

7.07 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Protagonist Therapeutics Inc

PTGX

7.04 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Krystal Biotech Inc

KRYS

7.01 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

The Stock Score data is powered by TradingKey and updated daily. Rating data is sourced from LESG. Please use the data with caution for reference purposes only.